Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HEXA | P06865 | 1/20 | 0.31 |
| ▸ | HEXB | P07686 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12928328 | 1.00 | ALDH1A1 (0.37) | ALDH1A1TSHRACHEMAOBKDM4E | |
| SCHEMBL14099722 | 0.93 | ACHE (0.41) | ALDH1A1ACHEKDM4EMAPTHPGD | |
| SCHEMBL13615643 | 0.93 | ACHE (0.37) | ALDH1A1TSHRACHEMAOBKDM4E | |
| SCHEMBL15762783 | 0.93 | ACHE (0.37) | ALDH1A1TSHRACHEMAOBKDM4E | |
| SCHEMBL14099861 | 0.93 | ACHE (0.37) | ALDH1A1TSHRACHEMAOBKDM4E | |
| SCHEMBL13886621 | 0.92 | ACHE (0.40) | ALDH1A1ACHEKDM4EMAPTHPGD | |
| SCHEMBL14099724 | 0.92 | ACHE (0.40) | ALDH1A1ACHEKDM4EMAPTHPGD | |
| SCHEMBL14516038 | 0.92 | ACHE (0.40) | ALDH1A1ACHEKDM4EMAPTHPGD | |
| SCHEMBL14099703 | 0.92 | ACHE (0.40) | ALDH1A1ACHEKDM4EMAPTHPGD | |
| SCHEMBL15762765 | 0.92 | ACHE (0.40) | ALDH1A1ACHEKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090273277-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
| US-20090273277-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090273277-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, ORMDL3, CHRM2 | ALDH1A1 818/4885TSHR 3938/4885ACHE 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.